<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478968</url>
  </required_header>
  <id_info>
    <org_study_id>MINI.C160.20.001</org_study_id>
    <nct_id>NCT04478968</nct_id>
  </id_info>
  <brief_title>Approach to Vascular Access After Renal Transplantation</brief_title>
  <acronym>AVART</acronym>
  <official_title>The Levels of Fibrosis Biomarkers in Patients After Renal Transplantation in Relation to Arteriovenous Fistula Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wroclaw Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to assess the effect of functioning AVF in renal transplant&#xD;
      patients on fibrosis, inflammation and LVH indicators. Clinical and laboratory parameters&#xD;
      will be compared in a group of 150 patients, 75 patients with a functioning fistula and 75&#xD;
      patients with inactive vascular access. We will assess the impact of functional AVF and the&#xD;
      levels of biomarkers on the survival of patients and transplanted kidneys.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients after kidney transplantation during a routine visit will be asked to participate to&#xD;
      the study. In eligible a number of studies will be conducted:&#xD;
&#xD;
        -  detailed clinical examination&#xD;
&#xD;
        -  routine laboratory tests&#xD;
&#xD;
        -  lung ultrasound&#xD;
&#xD;
        -  muscle strength with a dynamometer&#xD;
&#xD;
        -  ultrasound assessment of upper limb vessels with assessment of fistula function (in the&#xD;
           case of active fistula) and for the possibility of future vascular access&#xD;
&#xD;
        -  blood collection and protection (10-15 ml) for biomarkers&#xD;
&#xD;
        -  survey EQ-5D-5L and LVD-36&#xD;
&#xD;
        -  functional strength test.&#xD;
&#xD;
      The obtained clinical data and test results will be subject to statistical analysis after&#xD;
      anonymization. The impact of individual parameters on long-term prognosis will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">January 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life with EQ-5D-5L</measure>
    <time_frame>Baseline visit up to 12 months</time_frame>
    <description>The survey results will be compared between the study and control groups to see if the presence of the arteriovenous fistula affects quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prognostic value of biomarkers (NT-proBNP, Il-6, sST2, galectin-3, GDF-15, MMP7, TIMP1)</measure>
    <time_frame>Baseline visit and up to 12 months</time_frame>
    <description>The levels of biomarkers will be measured and the results will be compared between the study and control groups. A prognostic value of the biomarkers will be estimated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization-free survival</measure>
    <time_frame>Up to 12 months from baseline visit</time_frame>
    <description>Hospital-free survival will be reported as the number of patients living 12 months after the initial visit without the need for hospitalization.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Active AVF</arm_group_label>
    <description>Patients after kidney transplantation with functioning AVF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No AVF</arm_group_label>
    <description>Patients after kidney transplantation without AVF (thrombosed AVF, history of HD with catheter, history of PD, preemptive transplantation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>presence of AVF</intervention_name>
    <description>Functioning AVF may have cardiotoxic potential</description>
    <arm_group_label>Active AVF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have had a kidney transplant belong to the group of patients at increased risk&#xD;
        for cardiovascular disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age&gt; 18 years old&#xD;
&#xD;
          -  kidney transplant&#xD;
&#xD;
          -  &gt;12 months after transplantation&#xD;
&#xD;
          -  stable transplanted kidney function&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GFR &lt;15 ml / min&#xD;
&#xD;
          -  severe infection within 3 months of testing&#xD;
&#xD;
          -  increase in creatinine concentration&gt; 0.5 mg / dl within 3 months before the test&#xD;
&#xD;
          -  active cancer&#xD;
&#xD;
          -  signs of severe heart failure (NYHA IV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krzysztof Letachowicz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wroclaw Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Krzysztof Letachowicz, MD, PhD</last_name>
    <phone>+48717332546</phone>
    <email>krzysztof.letachowicz@umed.wroc.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nephrology and Transplantation Medicine</name>
      <address>
        <city>Wroclaw</city>
        <zip>55-556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Letachowicz, MD, PhD</last_name>
      <phone>+48717332546</phone>
      <email>krzysztof.letachowiocz@umed.wroc.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arteriovenous Fistula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

